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In most cases facioscapulohumeral muscular dystro-
phy (FSHD) is caused by contraction of the D4Z4 re-
peat in the 4q subtelomere. This contraction is asso-
ciated with local chromatin decondensation and
derepression of the DUX4 retrogene. Its complex ge-
netic and epigenetic cause and high clinical variabil-
ity in disease severity complicate investigations on
the pathogenic mechanism underlying FSHD. A vali-
dated cellular model bypassing the considerable het-
erogeneity would facilitate mechanistic and therapeu-
tic studies of FSHD. Taking advantage of the high
incidence of somatic mosaicism for D4Z4 repeat con-
traction in de novo FSHD, we have established a
clonal myogenic cell model from a mosaic patient.
Individual clones are genetically identical except for
the size of the D4Z4 repeat array, being either normalor FSHD sized. These clones retain their myogenic
characteristics, and D4Z4 contracted clones differ
from the noncontracted clones by the bursts of ex-
pression of DUX4 in sporadic nuclei, showing that
this burst-like phenomenon is a locus-intrinsic fea-
ture. Consequently, downstream effects of DUX4 ex-
pression can be observed in D4Z4 contracted clones,
like differential expression of DUX4 target genes. We
also show their participation to in vivo regeneration
with immunodeficient mice, further expanding the
potential of these clones for mechanistic and thera-
peutic studies. These cell lines will facilitate pairwise
comparisons to identify FSHD-specific differences
and are expected to create new opportunities for
high-throughput drug screens. (Am J Pathol 2012, 181:
1387–1401; http://dx.doi.org/10.1016/j.ajpath.2012.07.007)
Facioscapulohumeral muscular dystrophy (FSHD) affects
approximately 1:20,000 people and is thereby the third
most common myopathy after Duchenne muscular dys-
trophy and myotonic dystrophy. FSHD is clinically char-
acterized by progressive weakness and wasting of the
facial, shoulder, and upper arm muscles, often followed
by a widespread dystrophy during adulthood.1
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pattern of inheritance being caused by contraction of the
D4Z4 macrosatellite repeat in the subtelomeric region of
chromosome 4q (FSHD1).2 Normal alleles contain be-
tween 11 and 100 D4Z4 repeat units ordered head-to-tail,
whereas, in patients with FSHD1, one of the chromo-
somes 4 carries an array of 1 to 10 D4Z4 units.3 Contrac-
tion of the D4Z4 repeat is associated with reduced levels
of repressive chromatin markers; although D4Z4 is nor-
mally densely CpG methylated, D4Z4 at the disease al-
lele is hypomethylated in FSHD and contains reduced
levels of the heterochromatic modification histone 3
lysine 9 trimethylation.4–6 There is a second, less com-
mon form of FSHD, FSHD2, whereby patients are pheno-
typically indistinguishable from FSHD1 and display a sim-
ilar loss of repressive chromatin markers, but in the
absence of D4Z4 repeat contraction.5,7
Each D4Z4 unit contains a copy of the DUX4 retro-
gene,8,9 which led to the hypothesis that incomplete chro-
matin silencing at D4Z4 causes inappropriate expression of
DUX4 in FSHDmuscle. Initially, this hypothesis could not be
verified; DUX4 transcripts could not be detected in FSHD
muscle, shifting the focus to other chromosome 4qter genes
such as FRG1 and FRG2 as potential candidate genes.
Recent genetic and molecular data, however, provide
strong evidence for DUX4 expression in skeletal muscle
being causally related to FSHD pathogenesis.
The genetic evidence that supports a role for DUX4
comes from the observation that the subtelomere of chro-
mosome 10q contains an almost identical D4Z4-repeat
array, but contractions of this repeat are generally non-
pathogenic. In addition, different haplotypes of 4q have
been identified on the basis of the presence of sequence
variants in and around the D4Z4 repeat, and only D4Z4
contractions on specific genetic backgrounds of 4q, the
so-called permissive chromosomes 4, such as 4A161,
cause FSHD.10 FSHD-permissive chromosomes contain
an additional DUX4 exon with a polyadenylation signal im-
mediately distal to the most telomeric D4Z4 unit.11,12 Non-
pathogenic haplotypes, on the contrary, do not have this
exon or polyadenylation signal. Because this polyadenyla-
tion signal enables the stabilization of the DUX4 transcript
generated from the distal D4Z4 unit in skeletal muscle of
patients with FSHD1, these data strongly support a caus-
ative role for the stabilized DUX4 transcript expressed from
the telomeric D4Z4 unit in the pathogenesis of FSHD.
Molecular data support the genetic and epigenetic
data for a pathogenic role for the DUX4 gene in FSHD.
Overexpression models show that DUX4 is toxic to many
cells.13–16 DUX4 protein expression causes cell death in a
variety of cell types with skeletal muscle being highly sen-
sitive. Although early studies did not detect endogenous
DUX4 mRNA in FSHD skeletal muscle, more sensitive PCR-
based assays have identified FSHD-associated transcripts
from the telomeric D4Z4 unit.12 More specifically, expres-
sion of a full-length DUX4 transcript in muscle biopsies and
muscle cell cultures of patients with D4Z4 contraction
(FSHD1) and patients without D4Z4 contraction (FSHD2)
has been identified, which could not be detected in muscle
or in muscle cell cultures from control subjects.11,17 DUX4 is
normally expressed as a germline transcription factor, andits activity in skeletal muscle of patients with FSHD leads to
the activation of germline and early developmental pro-
grams, as well as the activation of retrotransposons and
suppression of innate immune genes.18
Somatic mosaicism for the D4Z4 contraction can be
observed in almost 50% of de novo FSHD1 families.19
These persons have experienced a postzygotic contrac-
tion of the D4Z4 repeat, generally resulting in the pres-
ence of two cell populations: one population of cells with
normal-sized D4Z4 repeats (noncontracted) and one
population of cells with one FSHD-sized D4Z4 repeat
(D4Z4 contracted) because of a contraction. Thus, for a
mosaic person, the genome of the D4Z4 contracted and
the noncontracted cells are identical except for the pres-
ence or absence of a contracted allele. Mosaicism for
D4Z4 repeat sizes in these persons can be observed at
roughly equal frequency in blood, muscle, and skin.20
Taking advantage of the high frequency of somatic mo-
saicism for the D4Z4 repeat contraction in patients with
de novo FSHD1, we generated and characterized clonal
immortalized myogenic cell lines from a mosaic patient
with FSHD1. With the use of a well-established immortal-
ization strategy,21 we have overcome the low proliferative
potential of primary myoblasts. Hereby, we have created
isogenic FSHD and normal myogenic cell lines from a
single person which can be used for molecular and drug
development studies. With the use of cell lines derived
from these patients with mosaic FSHD, we expect to
overcome some of the genetic and phenotypic variability
often observed in human studies because these cell lines
are isogenic except for the D4Z4 repeat size.
Materials and Methods
Patient
A needle muscle biopsy from a patient with mosaic FSHD
was obtained after informed consent. Mosaicism was
determined by genetic tests, and FSHD was clinically
confirmed, as described in Lemmers et al22,23 (see family
24). Briefly, the patient was seen at 37 years of age for
progressive weakness of proximal lower limb muscles
which had lasted for 2 years with a recent onset of foot
extensor weakness. On physical examination, shoulder
girdle weakness was present as well, and, with hindsight,
the patient recalled decreased strength in his arms from
the age of 28 years. Considerable asymmetrical facial
weakness was present. Pulsed field gel electrophoresis
(PFGE) analysis of DNA isolated from peripheral blood
cells showed mosaicism for a D4Z4 contraction. The pa-
tient had two equally prevalent cell populations, one allele
with a repeat of 13 D4Z4 units and one in which this allele
was contracted to 3 D4Z4 repeat units. As confirmed by
simple sequence length polymorphism analysis performed
as previously described,10 the mosaicism in this mosaic
patient occurred on a permissive 4A161 chromosome.
Within this context, a needle muscle biopsy was obtained
from the biceps of this mosaic patient at 54 years of age.
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Immortal clones were generated as previously de-
scribed.21 Briefly, the muscle biopsy was minced, and
the explants were plated onto culture dishes coated with
fetal calf serum and cultivated in growth medium [one-
quarter Medium 199 (Life Technologies, Carlsbad, CA)
plus three-quarters Dulbecco’s modified Eagle’s medium
(DMEM) high glucose supplemented with 20% fetal bo-
vine serum (FBS), 1% penicillin/streptomycin, 1% glu-
cose, 1% GlutaMAX and dexamethazone (107 mol/L
final volume), and 2.5 ng/mL recombinant hepatocyte
growth factor (Life Technologies)]. The myogenic cells
were allowed to migrate out of the explants and were
further expanded and enriched with the use of CD56-
magnetic microbeads (Miltenyi Biotec, Auburn, CA) ac-
cording to the manufacturer’s instructions. The purified
myoblasts were then transduced by two retroviruses car-
rying hTERT or Cdk4 genes containing either the puro-
mycin or neomycin resistance gene, respectively. After
selection, the immortalized population was cloned with the
use of glass cylinders. The proportion of myoblasts was
established by desmin labeling (first antibody: desmin
clone D33, mouse IgG1; 1:50; Dako; secondary antibody:
Alexa-555 goat anti-mouse, 1:400; Life Technologies).
Genetic Characterization of Clonal Myoblast
Cell Lines
The clonal myoblast cell lines were tested for the pres-
ence or absence of the D4Z4 contraction by PFGE, es-
sentially as previously described.10 Complete genetic
testing results, including D4Z4 repeat sizes and chromo-
somes 4 and 10 haplotypes of the patient participating in
this study, was already available.22,23 Briefly, 5  105
cells of each myogenic clone were embedded in agarose
plugs and after pronase (Roche Applied Science, India-
napolis, IN) treatment, digested with EcoRV (Fermentas,
Hanover, MD). As a control, agarose-embedded DNA
plugs derived from peripheral blood lymphocytes from
this patient were used. EcoRV was used instead of the
combination of EcoRI and BlnI, because previous geno-
typing studies on the peripheral blood cells of the patient
showed that the D4Z4 repeat array on chromosome 4B
and chromosome 10 were equal in size, both being 80
kb. EcoRV can discriminate between these repeat arrays
because of the different position of the distal EcoRV re-
striction site.22 Digested DNA was separated by PFGE,
and D4Z4 repeat sizes were visualized by sequential
hybridization with radioactive probes p13E-11 and D4Z4.
Immunofluorescence Staining
The myogenic purity of the clones was determined by
counting desmin-positive cells as a percentage of total
cells. Cells were cultivated in growth medium, fixed in 95%
ethanol, and incubated in 5% fetal calf serum in PBS for 30
minutes. The cultures were then incubated at 37°C for 2
hours with the primary antibody specific for desmin (clone
D33, mouse igG1, 1:50; Dako). Specific antibody binding
was shown with Alexa-555 goat anti-mouse (1:400; LifeTechnologies). To visualize nuclei, cells were mounted in
medium (Mowiol; Calbiochem-Novabiochem, Nottingham,
United Kingdom) containing bis-benzimide (0.0001% w/v;
Hoechst; Sigma-Aldrich, Indianapolis, IN). All images were
visualized with an Olympus BX60 microscope (Olympus
Optical, Tokyo, Japan), digitalized with the Photometrics
CoolSNAP fx CCD camera (Roper Scientific, Trenton, NJ),
and analyzed with the MetaVue image analysis software
version 7.0r4 (Molecular Devices, Sunnyvale, CA).
For coimmunofluorescence staining of DUX4 and pan-
myosin heavy chain (MHC), cells were fixed in 2% parafor-
maldehyde for 7 minutes at room temperature and then
washed twice with PBS. Cells were permeabilized with 1%
Triton X-100 (Sigma-Aldrich) in PBS for 10 minutes at room
temperature with gentle rocking. Primary rabbit-DUX4 anti-
body directed against the C-terminal region of humanDUX4
(E5-5; 1:100)24 and antibody against MHC (MF20, mouse
IgG2b, 1:100; Developmental Studies Hybridoma Bank,
Iowa City, IA) were diluted in PBS, and cells were incubated
overnight at 4°C with the first antibody, washed three times
with PBS, followed by incubation with 1:400 diluted Alexa
Fluor 488-conjugated donkey anti-rabbit and Alexa Fluor
594-conjugated donkey anti-mouse polyclonal antibody for
1 hour, gently rocking in the dark. Next, cells were washed
three times with PBS/0.025% Tween before they were
mounted on microscope slides with the use of Aqua Poly/
Mount (Polysciences, Inc., Warrington, PA) containing 500
ng/mL DAPI. Stained cells were analyzed on a Leica
DMRA2 microscope (Leica, Wetzlar, Germany).
Fusion Index
Cells (7  105) were grown in a 60-mm plate in growth
medium. One day later, the medium was removed, the
cells were washed with PBS, and differentiation medium
(DMEM supplemented with 10 g/mL insulin, 100 g/mL
transferring, and 50 g/mL gentamicin; Sigma-Aldrich)
was added. The cultures were fixed at day 3 or day 5 after
induction of differentiation with 100% ethanol, and MHC
labeling was performed (MF20, mouse IgG2b, 1:20 dilution;
Developmental Studies Hybridoma Bank). The efficiency of
the fusion was assessed by counting the number of nuclei
in differentiated myotubes (3 myonuclei) as a percentage
of the total number of nuclei (mononucleated and pluri-
nucleated). Statistical analysis was performed by two-sam-
ple t-test with P  0.01 considered to be significant.
RNA Isolation and cDNA Synthesis
For RNA isolation, five D4Z4 contracted and five noncon-
tracted myogenic clones were grown in 100-mm diame-
ter Petri dishes until 40% to 50% confluence to minimize
spontaneous differentiation. Myotubes were obtained by
growing the cells until 80% confluence, then switching
them to serum-deprived conditions (DMEM supple-
mented with 10 g/mL insulin, 100 g/mL transferrin, and
50 g/mL gentamicin) for 5 days. Total RNA was isolated
from proliferating and differentiated cultures with the use
of miRNeasy kit (Qiagen, Valencia, CA), including DNaseI
treatment according to the instructions of the manufac-
turer. The RNA concentration of the samples was deter-
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(Thermo Scientific, Waltham, MA), and the quality of the
RNAwas analyzed with a RNA 6000 nanochip on an Agilent
2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA).
Table 1. List of Primers and Corresponding Sequencing Used fo
Primer Sequence
GUS
Forward 5=-CTCATTTGGAATTTTGCCGATT-3=
Reverse 5=-CCGAGTGAAGATCCCCTTTTTA-3=
MYOG
Forward 5=-GCCAGACTATCCCCTTCCTC-3=
Reverse 5=-GGGGATGCCCTCTCCTCTAA-3=
MYH2A
Forward 5=-TGGCAAAATACAGGGGACTC-3=
Reverse 5=-CCAAAGCGAGAGGAGTTGTC-3=
MYOD1
Forward 5=-TACGAAGGCGCCTACTACAAC-3=
Reverse 5=-AGGCAGTCTAGGCTCGACAC-3=
FRG1
Forward 5=-GGCGGGTTCTACAGAGACG-3=
Reverse 5=-TTCTGGACGAGTATGTGAGTCG-3=
FRG2
Forward 5=-GGGAAAACTGCAGGAAAA-3=
Reverse 5=-CTGGACAGTTCCCTGCTGTGT-3=
DUX4
Forward 5=-CCCAGGTACCAGCAGACC 3=
Reverse 5=-TCCAGGAGATGTAACTCTAATCCA-
fllDUX4
Forward 5=-CCTGGGATTCCTGCCTTCTA-3=
Reverse 5=-AGCCAGAATTTCACGGAAGA-3=
PITX1
Forward 5=-ACATGAGCATGAGGGAGGAG-3=
Reverse 5=-GTTACGCTCGCGCTTACG-3=
RFPL2
Forward 5=-CCCACATCAAGGAACTGGAG-3=
Reverse 5=-TGTTGGCATCCAAGGTCATA-3=
TRIM43
Forward 5=-ACCCATCACTGGACTGGTGT-3=
Reverse 5=-CACATCCTCAAAGAGCCTGA-3=
DEFB103
Forward 5=-TGTTTGCTTTGCTCTTCCTG-3=
Reverse 5=-CGCCTCTGACTCTGCAATAA-3=
KHDC1
Forward 5=-ACCAATGGTGTTTCACATGG-3=
Reverse 5=-TGAATAAGGGTGTGGCTGTG-3=
MURF1
Forward 5=-CTTGACTGCCAAGCAACTCA-3=
Reverse 5=-CAAAGCCCTGCTCTGTCTTC-3=
ATROGIN-1
Forward 5=-AAAGAGCGCCATGGATATTG-3=
Reverse 5=-CTCAGGGATGTGAGCTGTGA-3=
TP53
Forward 5=-GTTCCGAGAGCTGAATGAGG-3=
Reverse 5=-TCTGAGTCAGGCCCTTCTGT-3=
MBD3L2
Forward 5=-CGTTCACCTCTTTTCCAAGC-3=
Reverse 5=-AGTCTCATGGGGAGAGCAGA-3=
PRAMEF1
Forward 5=-CTCCAAGGACGGTTAGTTGC-3=
Reverse 5=-AGTTCTCCAAGGGGTTCTGG-3=
ZSCAN4
Forward 5=-AACAAGTGAATGCCCAAACC-3=
Reverse 5=-TGTTCCAGCCATCTTGTTCA-3=
CCNA1
Forward 5=-CAACTTCCTGGACAGGTTCC-3=
Reverse 5=-TTCGAAGCCAAAAGCATAGC-3=
GAPDH
Forward 5=-AAGGTCGGAGTCAACGGATTT-3=
Reverse 5=-ACCAGAGTTAAAAGCAGCCCTG-3=RNA samples having a RNA integrity number score be-
tween 9.5 and 10 were used in this study.
cDNA was synthesized with 1 or 3 g of total RNA (de-
pending on the gene to be amplified; Table 1) with the use
Analysis
Temperature (°C) RNA input (g)
60 and 62 1 or 3
60 1
60 1
60 1
60 1
60 3
62 3
60 3
58 1
60 1
60 1
60 1
60 1
58 1
58 1
58 1
58 1
58 3
60 1
58 1
60 1r qPCR
3=
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with oligo dT-primed primers (Fermentas) according to the
manufacturer’s instructions. The cDNA was subsequently
treated with 0.5 U RNase H for 20 minutes at 37°C, and total
cDNA was diluted in 50 L of water. For real-time RT-PCR
analysis, cDNA was diluted 10-fold.
Quantitative RNA Expression Analysis
All quantitative RT-PCR (qPCR) analyses were performed
in duplicate with the use of SYBR green mastermix on the
MyIQ or CFX system (Bio-Rad, Hercules, CA), using 0.5
pmol/L of each primer in a final volume of 10 L per
reaction. For gene expression analysis 3 L of diluted
cDNA was used per reaction. Cycling conditions were as
follows: initial denaturation step at 95°C for 3 minutes,
followed by 40 cycles of 10 seconds at 95°C and 45
seconds at 58°C, 60°C, or 62°C according to the primer
used (see Table 1). Specificity of all reactions was mon-
itored by standard gel electrophoresis and/or melting
curve analysis: initial denaturation step at 95°C, followed
by 1 minute of incubation at 65°C and sequential tem-
perature increments of 0.5°C every 10 seconds up to
95°C. All primer sets (Table 1) were designed with
Primer3 software (http://www.bioinformatics.nl/cgi-bin/
primer3plus/primer3plus.cgi) and, for cDNA analysis, de-
signed to span at least one intron. Data were analyzed with
Bio-Rad CFX manager version 2.0. Relative expression was
calculated, using -glucuronidase (GUS) as a reference for
cDNA input, using the CFX manager software version 2.1
(Bio-Rad). Statistical analyses were performed by two-sam-
ple t-tests with P  0.05 considered to be significant.
Regeneration Potential in Vivo
To determine the in vivo regeneration capacity of these
isogenic clones with or without D4Z4 contraction, cells
were injected into the tibialis anterior (TA) of 3-month-old
female immunodeficient mice Rag2/ C/ C5/ (n
4 for each clone). TAs were cryo-damaged before injec-
tion to induce muscle regeneration, and 5  105 cells
were injected at a single point, as described previ-
ously.25 One month later, the mice were sacrificed, and
the muscles were removed and frozen in isopentane
cooled in liquid nitrogen and stored at 80°C. Serial
transverse sections (5 m) of the muscles on glass slides
were generated with a cryotome (Thermo Shandon, Inc.,
Pittsburgh, PA). Muscle was sectioned every 100 m
along the length of the muscle, and, in between, cryo-
sections were conserved at 80°C for further RNA anal-
ysis. The frozen sections were stained with human-spe-
cific lamin A/C antibody (clone JOL2, mouse IgG1; 1:300;
Abcam, Inc., Cambridge, MA) and human-specific spectrin
antibody (NCL-Spec1, clone RBC2/3D5, mouse IgG2b,
1:50, Novocastra, Newcastle, United Kingdom) for 1 hour.
The secondary antibodies used were cyanine 3-conjugated
goat anti-mouse IgG1 (Jackson ImmunoResearch Labora-
tories Inc., West Grove, PA) and Alexa Fluor 488 goat anti-
mouse IgG2b (Molecular Probes, Eugene, OR), respec-
tively. The number of human spectrin-positive fibers andlamin A/C-positive nuclei were calculated on the cryosec-
tion with the best number of spectrin-positive fibers.
The RNA extraction was performed after completed
dissociation of muscle sections with the use of 1 mL of
TRIzol according to the manufacturer’s protocol (Life
Technologies). The RNA pellets were resuspended in 10
L of RNase-free water.
Results
Generation and Characterization of Immortalized
Isogenic Human Myoblast Clones
To overcome the limited life span and genetic variability
of primary myoblast cultures, we have immortalized pri-
mary myoblasts obtained from a biceps muscle biopsy of
a patient with mosaic FSHD1. By using CD56 magnetic-
activated cell sorting, the myoblast cell population was
enriched before immortalization by stable transduction
with a hTERT- and a Cdk4-expressing retroviral vec-
tor.26,27 hTERT- and Cdk4-positive cells were cloned and
individual clones were expanded. In patients with mosaic
FSHD, contraction of D4Z4 occurs after fertilization; thus,
two types of myogenic clones are to be expected from
the immortalized population: those with D4Z4 contraction
and those without a contraction of the D4Z4 repeat array.
With the use of PFGE, individual clones were thus
screened for the presence or absence of D4Z4 contrac-
tion. The percentage of mosaicism was expected to be
50%, based on the frequencies observed in peripheral
blood cells of this patient. The repeat sizes of the allele
that underwent a somatic contraction are 13 D4Z4 units
for the noncontracted cells and 3 D4Z4 units for the D4Z4
contracted cells. Hybridization of EcoRV-digested gDNA
with probe p13E-11 showed that individual clones dis-
played either a contracted D4Z4 repeat array of 17 kb (3
units) or the original array of 48 kb (13 units). A repre-
sentative PFGE blot of a few selected clones is shown in
Figure 1. In total, five D4Z4 noncontracted and five D4Z4
contracted clones were used for further characterization
(see Supplemental Table S1 at http://ajp.amjpathol.org).
Thus, by clonal expansion, we established a panel of
immortalized muscle cell clones that are genetically iden-
tical, with the exception of the D4Z4 repeat size and of
the integration sites of the immortalization genes.
Morphology and Myogenic Characteristics of
Clones with or without D4Z4 Contraction
The proportion of myogenic cells in all immortalized mus-
cle cell clones was determined by the percentage of
desmin-positive cells. Immunofluorescence analysis
showed 100% desmin-positive cells in all clones (data
not shown). Next, the fusion index was determined, and
steady state expression levels of differentiation markers
were quantified during proliferation and after several
days in differentiation conditions, that is, serum starva-
tion. The fusion index was determined in D4Z4 con-
tracted and noncontracted clones at days 3 and 5 of
differentiation (Figure 2; n  3). At day 3, the fusion index
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than in the D4Z4 noncontracted clones (75%  7% vs
52%  4%; P  0.006), with low intervariability within the
three D4Z4 contracted and noncontracted clones. How-
ever, after 5 days of differentiation, the enhanced fusion
index observed in D4Z4 contracted clones did not reach
significance (78%  14% vs 64%  8% for D4Z4 con-
tracted and noncontracted clones, respectively; P 
0.19). At the transcriptional level, expression levels of the
myogenic commitment gene MYOD1 and the early and
late myogenic differentiation markers myogenin (MYOG)
and fast myosin heavy chain 2A (MYH2A) were evaluated
in the D4Z4 contracted and noncontracted clones during
proliferation and 5 days after differentiation (Figure 3). In
proliferating cells, MYOD1 levels were abundantly pres-
ent with no difference between the D4Z4 contracted and
noncontracted clones (Figure 3A). However, the myo-
genic differentiation markers MYOG and MYH2A were
significantly increased in D4Z4 contracted clones com-
pared with the noncontracted clones (P  0.04 and P 
0.02, respectively; Figure 3, C and E). Although being
isogenic, the expression levels of these myogenic mark-
ers differ between the D4Z4 contracted clones with clone
12 displaying the greatest increase. Because the high
increase in clone 12 was observed in three independent
cell-culturing experiments, its response appears to be
cell autonomous and not because of differences in cell
culture conditions.
As expected, higher MYOG and MYH2A transcript lev-
els were observed in differentiated cells compared with
the level detected during proliferation (data not shown).
MYOD1 levels were comparable in the proliferative and
Figure 1. PFGE analysis of isogenic myogenic clones of a patient with
mosaic FSHD. High-quality DNA isolated from the peripheral blood lympho-
cytes (P) and isogenic myogenic clones of a patient with mosaic FSHD were
digested with EcoRV and hybridized with probe p13E-11. The arrows depict
the mosaic alleles and the asterisk indicates chromosome 10-specific bands.
Myogenic clones A2 and A5 contain only the contracted allele.differentiation phase. In myotubes, no significant differ-ence in MYOD1 and MYOG levels could be detected
between D4Z4 contracted and noncontracted clones
(Figure 3, B and D), whereas MYH2A showed signifi-
cantly lower transcript levels in the myotubes from the
D4Z4 contracted clones (P  0013; Figure 3F). Overall,
these data indicate that proliferating cells from the con-
tracted clones enter the myogenic differentiation pro-
gram prematurely.
Expression of 4qter Genes
To investigate the direct effect of the D4Z4 contraction on
4qter gene expression, transcript levels of FRG2, FRG1,
and DUX4 were determined by qPCR with the use of
intron-spanning primers (Table 1), during proliferation
and after 5 days of differentiation. Overall, FRG2 levels in
proliferating clones were low and only detectable when
increasing RNA input. Although not significant, because
one noncontracted clone showed low FRG2 transcript
levels, the contracted clones showed increased FRG2
levels (Figure 4A). During differentiation, FRG2 expres-
sion levels were shown to be significantly enhanced in
the myotubes derived from D4Z4 contracted clones com-
pared with the noncontracted clones (P  0.022; Figure
4B). However, absolute levels were still low. FRG1 tran-
script levels remain stable during myogenesis (see Sup-
plemental Figure S1 at http://ajp.amjpathol.org), and the
level of FRG1 transcripts did not differ between D4Z4
contracted and noncontracted clones both during prolif-
eration and after differentiation (Figure 4, C and D). To
quantify DUX4 levels during proliferation, the RNA input
levels needed to be increased. DUX4 was expressed in
all D4Z4 contracted clones, whereas it was absent or
barely detectable at the RNA level in the noncontracted
clones (Figure 5, A and B). In differentiated cells, DUX4
expression was increased in the D4Z4 contracted clones
and remained absent in noncontracted clones (Figure
5B). As for the myogenic markers, substantial variability
in DUX4 expression levels was observed between the
D4Z4 contracted clones in both proliferating and differ-
entiating conditions.
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Figure 2. Fusion index of isogenic myogenic clones of a patient with
mosaic FSHD. Cells were differentiated and fixed at day 3 or day 5 of
differentiation and stained for myosin. The efficiency of the fusion was
determined by counting the number of nuclei in differentiated myotubes
(3 myonuclei) as a percentage of the total number of nuclei. Values
represent the means  SDs; n  3 D4Z4 contracted versus n  3 D4Z4
noncontracted clones. **P  0.01.
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AJP October 2012, Vol. 181, No. 10Although DUX4 expression was significantly up-regu-
lated in the D4Z4 contracted clones, the abundance of
DUX4 mRNA transcripts remained low, similar to what
has been described in primary FSHD myotubes.12,17 To
test whether all nuclei of D4Z4 contracted clones express
small amounts of DUX4 protein or whether a subset of
myonuclei express DUX4 at appreciable levels, DUX4
immunofluorescence was performed. Three D4Z4 non-
contracted (3, A1, and A10) and three D4Z4 contracted
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Snon-contracted contracted non-contracted(12, A5, and A11) clones were cultured, fixed, and
costained with DUX4 and the myogenic marker pan-
MHC, both when proliferating and at day 5 of differenti-
ation. In agreement with previous data, in clonal cells
DUX4 protein is only expressed in a small proportion of
myonuclei in the D4Z4 contracted muscle clones. In ac-
cordance with our observations of DUX4 transcript levels,
DUX4-positive nuclei could already be detected in the
D4Z4 contracted clones during proliferation, but only in
12 A5 A2 A11
MYOD1
contracted
12 A5 A2 A11
MYOG
contracted
12 A5 A2 A11
MYH2A
contracted
Figure 3. Expression levels of the myogenic
markers, MYOD1, MyoG, and MYH2 during pro-
liferation and after differentiation. Transcript lev-
els were quantified in five D4Z4 contracted and
five D4Z4 noncontracted clones during prolifer-
ation (A, C, and E) and 5 days after induction of
differentiation (B, D, and F). Values represent
the means  SEMs. Clone A1 was used as the
reference, and its expression level was set at an
arbitrary value of 1. The calculations were inde-
pendently done for myoblasts and myotubes.
Values represent the means  SEMs. *P 0.05.
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FRG2
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FRG1
Figure 4. Expression levels of 4qter genes
FRG1 and FRG2 during proliferation and after
differentiation. Transcript levels were quantified
in five D4Z4 contracted and five D4Z4 noncon-
tracted clones during proliferation (A and C) and
5 days after induction of differentiation (B and D).
Clone A1 was used as the reference, and its ex-
pression level was set at an arbitrary value of 1.
Values represent the means  SEMs. *P  0.05.3 2
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AJP October 2012, Vol. 181, No. 10the highest expressers (clones A5 and 12), showing 1
DUX4-positive nucleus per 8000 nuclei (Figure 5C). Five
days after induction of differentiation, DUX4-positive
myonuclei could be detected in all three D4Z4 contracted
clones with an incidence that ranged between 1:1000
and 1:3000 positive myonuclei (Figure 5D). DUX4 pro-
tein–expressing myonuclei were never observed in any
of the noncontracted clones (data not shown).
Expression of Downstream Targets
Recently Geng et al18 described a DUX4 transcriptional
network that was based on transcriptome analysis com-
bined with chromatin immunoprecipitation studies of hu-
man myoblasts after lentiviral DUX4 transduction. They
identified a number of germline genes as direct or indi-
rect DUX4 targets. In our cellular model, we therefore
investigated the expression of a number of these and
previously identified direct or indirect DUX4 targets as
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Snon-contracted contracted non-contractedwell as other genes that have been proposed to be in-
volved in FSHD etiology: PITX1, MURF1, ATROGIN1,
TP53, CCNA1, MBD3L2, PRAMEF1, ZSCAN4, TRIM43,
RFPL2, KHDC1, and DEFB103.12,18,28–30 Their expres-
sion levels were evaluated during proliferation and at day
5 of differentiation by qPCR. For PITX1 and TP53, we
observed no quantitative differences in mRNA levels be-
tween D4Z4 contracted and noncontracted clones during
proliferation (Figure 6, A and C) or differentiation (Figure
6, B and D).
Of the muscle atrophy F-box (ATROGIN1) and muscle
ring-finger protein 1 (MURF1) genes, only MURF1 was
significantly up-regulated in the D4Z4 contracted clones
5 days after induction of differentiation (Figure 7, A–D).
The DUX4 target genes that are involved in germ cell and
early development, ZSCAN4, TRIM43, RFLP2, and
PRAMEF1,31–35 were all shown to be significantly in-
creased in the D4Z4 contracted cells during proliferation
(Figure 8,A, C, E, and G). The Methyl-CpG binding do-
2 12 A5 A2 A11
DUX4
contracted
Figure 5. DUX4 transcript and protein levels
during proliferation and after differentiation.
DUX4 transcript levels were quantified by qPCR
in five D4Z4 contracted and five D4Z4 noncon-
tracted clones during proliferation (A) and 5
days after induction of differentiation (B). The
lowest expression level was set at an arbitrary
value of 1. Values represent the means  SEMs.
D4Z4 contracted proliferating cells (C) and dif-
ferentiated cells (D) were costained with DUX4
and Myosin. A representative immunofluores-
cent picture of a D4Z4 contracted clone is de-
picted. Left panels show staining with DUX4.
Right panels show a merged picture of myo-
blast (C) and myotubes (D) costained with
DUX4 (in green) and MYH (in red) and counter-
stained with DAPI (in blue). Only contracted
clones show the characteristic pattern with a
subset of myonuclei expressing abundant levels
of DUX4 protein. *P  0.05.
12 A5 A2 A11
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TP53
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Figure 6. Expression levels of potential DUX4
downstream targets, PITX1 and TP53, during
proliferation and after differentiation. Transcript
levels were quantified by qPCR in five D4Z4
contracted and five D4Z4 noncontracted clones
during proliferation (A and C) and 5 days after
induction of differentiation (B and D). The lowest
expression level was set at an arbitrary value of 1.
Values represent the means  SEMs. P  0.05.3
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AJP October 2012, Vol. 181, No. 10main protein 3-like 2 (MBD3L2) gene that is also ex-
pressed in germ cells36,37 was not significantly deregu-
lated during proliferation (Figure 9C), but it did show a
significant increase in the D4Z4 contracted myotubes
(Figure 9D). In addition, ZSCAN4 and TRIM43 were sig-
nificantly up-regulated in the D4Z4 contracted clones 5
days after induction of differentiation (Figure 8, B and D).
During differentiation, RFPL2, PRAMEF1, CCNA1 encod-
ing cyclin 1A, which is highly expressed in testis,38,39 and
KHDC1, another gene early expressed in development,40
also seemed to be at higher abundance in the D4Z4
contracted clones, but, because their levels are also high
in one noncontracted clone (A1), it did not reach signifi-
cance (Figure 8, F and H, and Figure 9, B and F).
Previously, it was shown that DUX4 inhibits the innate
immune response, at least partly, through the induction of
DEFB103 (-defensin 3) expression.18 Therefore, we also
analyzed the expression of DEFB103 in our clones, indi-
cating a noticeable increase in the proliferating D4Z4
contracted clones, which was not significant because of
the increase in one of the noncontracted clones (A1)
(Figure 10A). In myotubes, no difference in DEFB103
expression between D4Z4 contracted and noncon-
tracted clones was observed (Figure 10B). DEFB103
has been recently shown to affect myogenesis partly
by increasing myostatin (MSTN) expression levels.18
Therefore, we also evaluated MSTN mRNA levels in the
D4Z4 contracted and noncontracted clones. Although
we have not observed a correlation between DEFB103
and MSTN expression levels, both showed a trend
toward up-regulation in the proliferated (Figure 10C)
but not in the differentiated D4Z4 contracted clones
(Figure 10D).
Contribution to Muscle Regeneration
Next, we determined the in vivo regeneration capacity of
the D4Z4 contracted and noncontracted clones and as-
sessed whether we could monitor expression of the
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SDUX4 responsive genes in the mouse muscle that wastransplanted. D4Z4 contracted (54.12) and noncon-
tracted (54.6) cells were injected into cryo-damaged TA
of 3-month-old female immunodeficient Rag2/ C/
C5/ mice. One month after injury, the mice were sac-
rificed, and the presence of newly generated human fi-
bers was identified by human spectrin (expressed in
differentiated fibers) staining. Human lamin A/C was used
to count the number of human nuclei within the muscle.
As depicted in Figure 11, A–C, both D4Z4 contracted and
noncontracted clones were efficiently incorporated into
the regenerating fibers with similar efficiency as de-
scribed previously for normal immortal cell clones.27 In-
terestingly, although only a fraction of the TA mouse
muscle fibers have been reconstituted with human mus-
cle fibers and considering that the proportion of DUX4-
positive cells will most likely be exceedingly low, because
only 1 of 1000 human myonuclei will express DUX4, we
did observe increased levels of the DUX4 responsive
gene, TRIM43, in the TA transplanted with the D4Z4 con-
tracted clones (Figure 11D). Although the levels were
too low to be quantified, in an independent experiment
that used a different set of D4Z4 contracted and non-
contracted clones, increased levels of DUX4 respon-
sive genes, such as TRIM43, ZSCAN4, and RFPL2,
could be identified in the D4Z4 contracted mouse muscle
that was transplanted (see Supplemental Figure S2 at
http://ajp.amjpathol.org).
Discussion
Our understanding of the pathogenic mechanism in
FSHD has greatly advanced in recent years. Leaky ex-
pression of the normally repressed DUX4 retrogene in
muscle appears to be a main hallmark of FSHD.11,17,41
The availability of this uniform disease model42 is ex-
pected to shift the research focus toward studies that
address the function and regulation of DUX4 and to
launch new incentives to identify molecules that can sup-
press DUX4 activity. Elucidation of downstream targets of
12 A5 A2 A11
MURF1
contracted
12 A5 A2 A11
ATROGIN 1
contracted
Figure 7. Expression levels of muscle-specific
E3 ubiquitin ligases, muscle ring finger 1
(MURF1) and Atrogin-1 during proliferation and
after differentiation. Transcript levels were quan-
tified by qPCR in five D4Z4 contracted and five
D4Z4 noncontracted clones during proliferation
(A and C) and 5 days after induction of differ-
entiation (B and D). The lowest expression level
was set at an arbitrary value of 1. Values repre-
sent the means  SEMs. *P  0.05.2
*
2DUX4 could also identify new therapeutic targets. These
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AJP October 2012, Vol. 181, No. 10studies will require validated cellular and animal model
systems.
Many biological variables affect the outcome of molec-
ular studies that use human biomaterials. These include,
but are not limited to, the genetic and phenotypic heter-
ogeneity of individuals, age, sex, and tissue heterogene-
ity, factors all known to influence the outcome of a study.
Indeed, a recent report indicates that in FSHD the factor
family of origin contributes significantly to cellular prop-
erties of myoblast cultures such as fusion rate and stress
response.43 Most likely these factors have contributed to
the inconsistent expression data reported in various
FSHD studies.28,30,44,45 Here, we attempted to overcome
some of these limitations by the generation of immortal-
ized isogenic FSHD muscle cell lines that genetically
differ only by the presence or absence of the disease-
associated D4Z4 contraction and the sites of transgene
integration. The generation of this cellular model opens
the possibility to investigate the direct effects of D4Z4
contraction with a minimum of genomic variables.
Previous reports showed that by the use of hTERT and
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SCDK4, immortalized human FSHD cell lines with a greatlyextended proliferative life span can be generated, and,
importantly, they were shown to maintain their capacity to
differentiate.21,26 In the present study, besides assessing
the in vitro and in vivo differentiation potential, the preser-
vation of FSHD-specific transcriptional signatures in the
D4Z4 contracted cell clones also has been addressed.
Of interest, the immortalization and clonal expansion pro-
cedure did not affect the molecular hallmark of FSHD
myoblast cultures; abundant amounts of DUX4 protein
could be detected in a small subset of myonuclei of
clones containing the contracted allele only. Moreover,
the overall low DUX4 expression levels in the D4Z4 con-
tracted clones significantly induced the expression of
established DUX4 target genes such as ZSCAN4,
TRIM43, RFPL2, PRAMEF1, MBD3L2,18 and MURF1.28
We also observed that in our D4Z4 contracted clones
P53, PITX1, and ATROGIN1, previously proposed to be
involved in FSHD,12,28,29 were not differentially ex-
pressed during either proliferation or after differentiation.
One of the five D4Z4 noncontracted clones (A1) shows
an atypical expression pattern. Although DUX4 protein
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TRIM43
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RFPL2
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Figure 8. Expression levels of DUX4 down-
stream targets, which normally are expressed in
germline, during proliferation and after differen-
tiation. Transcript levels were quantified in five
D4Z4 contracted and five D4Z4 noncontracted
clones during proliferation (A, C, E, and G) and
5 days after induction of differentiation (B, D, F,
and H). The lowest expression level was set at
an arbitrary value of 1. Values represent the
means  SEMs. *P  0.05.3 2
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3 2could not be detected 5 days after induction of differen-
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AJP October 2012, Vol. 181, No. 10tiation, DUX4 target genes such as PRAMEF1, ZSCAN4,
RFPL2, CCNA1, KHDC1, and DEFB103 are expressed in
this particular clone. This could be because of heteroge-
neity of the transduced population or more likely because
of the number and/or integration sites of the transgene.
This observation also emphasizes the importance of ex-
tensive screening of the clones before using them in
further studies. When removing clone A1 from the analy-
sis, two additional genes that recently have been identi-
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Snon-contracted contracted non-contractedfied in the DUX4 transcriptional network, CCNA1 and
KHDC1,18 are significantly increased in the D4Z4 con-
tracted clones. Overall, this isogenic immortalized cellu-
lar model retains the FSHD-specific characteristics, in-
cluding robust up-regulation of the recently identified
DUX4 target genes that could serve as good biomarkers
in future therapeutic intervention studies.
D4Z4 contracted clones have a significantly higher
fusion index concomitant with increased expression of
2 12 A5 A2 A11
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contracted
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KHDC1
contracted
2 12 A5 A2 A11
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Figure 9. Expression levels of DUX4 down-
stream targets, which normally are expressed in
germline or early during development, during
proliferation and after differentiation. Transcript
levels were quantified in five D4Z4 contracted
and five D4Z4 noncontracted clones during pro-
liferation (A, C, and E) and 5 days after induction
of differentiation (B, D, and F). The lowest ex-
pression level was set at an arbitrary value of 1.
Values represent the means  SEMs. *P  0.05.
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Figure 10. Expression levels of DEFB103 and
Myostatin in myoblasts and myotubes. Transcript
levels were quantified in five D4Z4 contracted and
five D4Z4 noncontracted clones during prolifera-
tion (A and C) and 5 days after induction of differ-
entiation (B and D). The lowest expression level
was set at an arbitrary value of 1. Values represent
the means  SEMs. P  0.05.3
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AJP October 2012, Vol. 181, No. 10the early and late myogenic differentiation markers
MYOG and MYH2A, respectively, at early stage of differ-
entiation. Differences in fusion index between FSHD and
control myoblasts to our knowledge have not been re-
ported before, possibly because of the high variation in
fusion rate between muscle cell cultures obtained from
different persons, especially when comparing FSHD
muscle cultures.43,46 This reinforces the strength of our
model; comparing D4Z4 contracted and noncontracted
clones obtained from a single person allowed us to un-
cover differences in fusion rate between D4Z4 contracted
or noncontracted clones in early stages of differentiation.
This is in agreement with reports of a defect in the myo-
genic pathway in FSHD myoblasts.47,48 For example,
Cheli et al47 showed increased MYOD1 transcripts in
proliferating FSHD myoblast. In accordance, Winokur et
al48 detected an increase in the early direct targets of
MYOD1. MYOD1 has been defined as one of the earliest
markers of myogenic commitment, triggering myogenic
differentiation, concomitant with an exit of the cell cy-
cle,49 followed by an increase in MYOG expression. Al-
though we did not assess a difference in MYOD1 levels,
the myogenic markers induced by MYOD1 during normal
myogenesis were significantly increased. So presum-
ably, the isogenic immortalized clones are in a more
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Figure 11. In vivo muscle formation with the use of noncontracted and
contracted clones. The TA of immunodeficient mice were cryodamaged
before being transplanted with 500,000 cells of either D4Z4 contracted or
noncontracted clones. One month after injury and implantation, mice (n 4)
were sacrificed, and TA was costained with human specific lamin A/C (in
red) and spectrin antibodies (in green). DAPI (in blue) was used to visualize
all of the nuclei. Panel A shows a representative image of TA either being
transplanted with noncontracted (left panel) or D4Z4 contracted clones
(right panel). The histograms show the number of spectrin-positive fibers
(B) and the number of Lamin A/C-positive nuclei (C). No significant
difference in regeneration potential of D4Z4 noncontracted and con-
tracted clones was observed. Values represent the means  SEMs. P 
0.05. D: TRIM43 transcript levels were quantified in TA muscle trans-
planted with either D4Z4 contracted (54.12) or noncontracted (54.6)
clone. Values represent the means  SEMs.activated state compared with the primary myoblast stud-ied in previous reports. Taking the kinetics of the myo-
genic markers during the myogenic program into consid-
eration, all these data are in agreement with the
premature entry into differentiation that we observed in
the contracted FSHD clones.
The DUX4 target gene DEFB103, formerly shown to be
involved in the host defense mechanism, seems also to
regulate myogenesis.18 In the isogenic clones, DEFB103
levels seem to be increased in the D4Z4 contracted
clones during proliferation and not after differentiation. In
support, MSTN, induced by DEFB103,18 was also in-
creased in proliferating D4Z4 contracted clones. Intrigu-
ingly, in primary myoblast cultures DEFB103 supplemen-
tation only alters MSTN expression in proliferating
myoblasts,18 consistent with elevated expression of
MSTN levels in the proliferating D4Z4 contracted clones.
Five days after induction of differentiation significantly
reduced MYH2A levels were apparent in the D4Z4 con-
tracted clones, which is in agreement with previous
data.47 Because myoblasts that were cultured for 3 days
in the presence of DEFB103 showed a decline in fu-
sion,18 our data might suggest that increased DUX4, pos-
sibly in part through increased DEFB103 levels, and in-
creased MSTN levels hinder the myogenic program at
later stages that involve muscle maturation, as indicated
by reduced MYH2A levels in the D4Z4 contracted clones.
FRG1 has been proposed as an FSHD candidate gene
on the basis of its transcriptional up-regulation in FSHD
muscle, and muscle-specific overexpression of FRG1 in
a transgenic mouse model leads to muscle dystro-
phy.50,51 However, expression studies have yielded in-
consistent results as to whether FRG1 is indeed up-reg-
ulated in FSHD.44,45,52 Interestingly, FRG1 expression is
not significantly different between D4Z4 contracted and
noncontracted clones, both during proliferation and after
differentiation. Thus, its role in FSHD pathogenesis re-
mains speculative. In contrast, FRG2 mRNA levels are
specifically increased in D4Z4 contracted clones, con-
sistent with published data.44,53 However, their expres-
sion levels remain low, and patients with FSHD with a
classical disease phenotype have been reported in
which the partial deletion of the D4Z4 repeat extended
proximally and also included the FRG2 locus.54
A more likely pathogenic factor in FSHD is DUX4 ex-
pressed from the telomeric D4Z4 unit. DUX4 induces
apoptosis in a p53-dependent manner in somatic cells,
including skeletal muscle, and interferes with myogenic
pathways as was shown in several overexpression mod-
els.14–16 DUX4 activates expression of early stem cell
and germline programs in skeletal muscle.18 Full-length
DUX4 (flDUX4) transcripts have only been detected in
FSHD myoblasts, myotubes, and skeletal muscle.17
FlDUX4 expression levels are low and not always detect-
able in FSHD muscle. We confirmed low flDUX4 expres-
sion in all contracted clones already during proliferation,
both by qPCR and immunofluorescence. However, on
differentiation, we observe higher DUX4 expression as
evidenced by an increased number of DUX4-positive
myonuclei. This observation supports a direct link be-
tween the genetic lesion and transcriptional derepression
of DUX4. It also argues that the pattern of occasional
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cific subtype of myoblasts that express DUX4 or by an
effect of the local milieu, but that this burst-like phenotype
is a locus-intrinsic property.
Unexpectedly, in proliferating cultures of D4Z4 non-
contracted clone A1 and in myotubes of D4Z4 noncon-
tracted clone 3, low levels of DUX4 transcripts could be
detected by qPCR. By RT-PCR we confirmed that these
clones express low levels of flDUX4 (see Supplemental
Figure S3 at http://ajp.amjpathol.org). Possibly, CDK4,
hTERT expression, or the integration event itself in these
noncontracted clones affects DUX4 expression. How-
ever, because we did not observe DUX4 protein or a
consistent increase in expression of DUX4 target genes
in these clones, the biological relevance of this observa-
tion remains unclear.
Characteristic for FSHD is the clinical variability in dis-
tribution and progression of muscle weakness. Although
some of these differences can be ascribed to the num-
ber of residual D4Z4 units,55–57 the clinical variability
between close relatives having the same disease allele
and the variable clinical presentation in monozygotic
twins58–60 suggest additional (epigenetic) factors. One
possibility is that the regulation of this characteristic phe-
notype of bursts of DUX4 expression contributes to the
variable clinical presentation. The data from our molecu-
lar profiling of our D4Z4 contracted clones, in this re-
spect, is remarkable. Although isogenic, the expression
levels of DUX4 and the coregulation of its targets in the
D4Z4 contracted clones are highly variable. In accor-
dance, the proportion of DUX4-positive myonuclei simi-
larly varied between the D4Z4 contracted clones. Differ-
ences in the molecular signature of isogenic cells,
cultured under the same environmental conditions and
sharing the same replicative history, have been docu-
mented, and stochastic gene expression has been
broadly explored for its biological implications. Variation
in expression levels can originate from mRNAs that are
synthesized in short but intense bursts of transcription.61
For DUX4, activation of the DUX4 promoter might be slow
and unstable, but producing many mRNA copies on each
activation event. Consequently, small differences in the
number of activation events will propagate to larger fluc-
tuations in DUX4 mRNA transcripts. Of interest, some
evidence exist that chromatin remodeling can contribute
to stochastic changes in gene expression. With the use of
chromatin-remodeling agents62,63 and of reporter con-
structs, it was shown that two identically regulated re-
porter genes integrated in two distinct chromosomes
showed uncorrelated bursts of expression. However,
when moved to adjacent sites in a single locus, their
mRNA expression pattern became almost fully corre-
lated.61 Because FSHD has an epigenetic etiology and
because the D4Z4-adjacent FRG2 gene showed the
same variation in mRNA transcript levels in the D4Z4
contracted clones as DUX4, it is possible that the chro-
matin remodeling machinery drives this stochastic ex-
pression pattern of DUX4 as against the transcription
machinery. Therefore, it will be important in future studies
to identify the factors that regulate DUX4 expression andto extend these studies in clonal myogenic cells of addi-
tional patients.
Previous transplantation experiments showed that im-
mortalized human myoblasts participate with higher effi-
ciency in regenerating mouse muscle than parental pri-
mary myoblasts.27 In the present report, we show that
both D4Z4 contracted and noncontracted immortalized
clones share the ability to participate in the regeneration
of new mature muscle in vivo. This provides a new model
to study the in vivo behavior of D4Z4 contracted and
noncontracted clones and the effect of gene deregulation
in this context. DUX4 is a primate-specific retrogene that
likely has acquired primate-specific functions and per-
haps cannot exert the same functions in mouse as it can
in humans. Therefore, it might be challenging to unravel
the consequences of DUX4 expression in skeletal muscle
in a mouse model that overexpresses DUX4. Transplan-
tation of D4Z4 contracted and noncontracted human
myoblast clones into injured mouse muscle, as we have
done in this study, while maintaining the unique FSHD
molecular phenotype of bursts of DUX4 expression in a
subset of human myonuclei will overcome this limitation;
in this experimental set up, DUX4 expression can be
examined in its natural context in vivo. In addition, it will
be possible to select the clones presenting a normal
karyotype, which retain their capacity to differentiate
and have integrated the hTERT and CDK4 inserts at an
innocuous location. Therefore, with current knowledge,
transplantation of immortalized D4Z4 contracted and
noncontracted FSHD clones into a mouse model will
represent a dedicated system to assess the short-term
consequence of DUX4 expression during muscle re-
generation in the absence or presence of drugs that
augment or suppress DUX4 levels. Indeed our prelim-
inary data suggest that human DUX4 targets can be
detected in this model when D4Z4 contracted clones
participate in regeneration.
In summary our data show that we have generated a
panel of isogenic immortal muscle cell lines that differ
only by the presence or absence of the D4Z4 contrac-
tion. In addition to their capacity to differentiate both in
vitro and in vivo, these muscle cell lines have main-
tained the molecular fingerprint of FSHD by displaying
differential expression of DUX4, FRG2, ZSCAN4,
TRIM43, RFPL2, PRAMEF1, MDB3L2, and MURF1,
which could be used as FSHD biomarkers. It is to be
expected that this panel of muscle cell lines will be a
valuable source for future FSHD studies and high-
throughput screenings.
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